Department of Rheumatology and Clinical Immunology.
Department of Rheumatology and Clinical Immunology and Department of Rehabilitation Medicine, University Medical Centre Groningen, Groningen.
Rheumatology (Oxford). 2021 Oct 2;60(10):4476-4485. doi: 10.1093/rheumatology/keab019.
Many patients with axial spondyloarthritis (axSpA) report persistent pain even when treated with anti-inflammatory agents. Our aim was to explore the presence of central sensitization (CS) and different types of illness perceptions in patients with axSpA, and to assess their associations with disease activity assessments.
Consecutive outpatients from the Groningen Leeuwarden Axial Spondyloarthritis (GLAS) cohort were included. Besides standardized assessments, patients filled out the Central Sensitization Inventory (CSI), Illness Perception Questionnaire (IPQ-R) and Pain Catastrophizing Scale (PCS). Univariable and multivariable linear regression analyses were used to investigate the association between questionnaire scores, patient characteristics and disease activity assessments ASDASCRP, BASDAI and CRP.
We included 182 patients with a mean symptom duration of 21.6 years. Mean ASDASCRP was 2.1, mean BASDAI 3.9, and median CRP 2.9. Mean CSI score was 37.8 (scale 0-100) and 45% of patients scored ≥40, indicating a high probability of CS. CSI score, IPQ-R domain identity (number of symptoms the patient attributes to their illness), and IPQ-R domain treatment control (perceived treatment efficacy), and obesity were significantly and independently associated with both ASDASCRP and BASDAI, explaining a substantial proportion of variation in these disease activity scores (R2=0.35 and R2=0.47, respectively). Only obesity was also independently associated with CRP.
CS may be common in patients with long-term axSpA. CS, as well as specific illness perceptions and obesity were all independently associated with the widely used (partially) patient-reported disease activity assessments ASDASCRP and BASDAI. Treating physicians should take this into account in the follow-up and treatment of their patients.
许多患有中轴型脊柱关节炎(axSpA)的患者即使接受了抗炎治疗仍报告存在持续性疼痛。我们的目的是探讨 axSpA 患者是否存在中枢敏化(CS)和不同类型的疾病认知,并评估它们与疾病活动评估的相关性。
连续纳入格罗宁根-吕伐登中轴型脊柱关节炎(GLAS)队列的门诊患者。除了标准评估外,患者还填写了中枢敏化量表(CSI)、疾病认知问卷(IPQ-R)和疼痛灾难化量表(PCS)。使用单变量和多变量线性回归分析来探讨问卷评分、患者特征与疾病活动评估 ASDASCRP、BASDAI 和 CRP 之间的关系。
我们纳入了 182 名平均病程为 21.6 年的患者。平均 ASDASCRP 为 2.1,平均 BASDAI 为 3.9,中位 CRP 为 2.9。CSI 评分的平均值为 37.8(范围 0-100),45%的患者评分≥40,表明存在较高的 CS 可能性。CSI 评分、IPQ-R 领域身份(患者归因于其疾病的症状数量)和 IPQ-R 领域治疗控制(感知的治疗效果)以及肥胖与 ASDASCRP 和 BASDAI 均显著且独立相关,分别解释了这些疾病活动评分中相当大的变异部分(R2=0.35 和 R2=0.47)。只有肥胖也与 CRP 独立相关。
CS 可能在长期 axSpA 患者中较为常见。CS 以及特定的疾病认知和肥胖均与广泛使用的(部分)患者报告的疾病活动评估 ASDASCRP 和 BASDAI 独立相关。治疗医生在随访和治疗患者时应考虑到这一点。